Open Label, Multicenter, Phase 1 Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 with Dose Expansion Phase, in Subjects with Advanced Solid Tumors
Details
Age
Adult
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
Jennifer Diamond
Study ID
Protocol Number: 22-0877
More information available at ClinicalTrials.gov: NCT03863145
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers